Similarly, current data demonstrated a more significant increase of IL-2 secretion upon LiposiRNA-Sig10L treatment at the dose of 80 pmols of siRNA versus untreated cells and not functionalized lipoplexes in HET C1858T PTPN22 T1D PBMC, using a suboptimal condition for stimulation with anti-CD3/CD28 beads (Figure 6 and Table S2). Here, PTPN22 is linked to type 1 diabetes mellitus.